Lyra Therapeutics Inc’s filing revealed that its Chief Financial Officer Cavalier Jason unloaded Company’s shares for reported $2587.0 on Jan 06 ’26. In the deal valued at $3.36 per share,769 shares were sold. As a result of this transaction, Cavalier Jason now holds 518,547 shares worth roughly $1.07 million.
Then, Palasis Maria sold 1,702 shares, generating $5,726 in total proceeds. Upon selling the shares at $3.36, the President & CEO now owns 1,096,733 shares.
Before that, Palasis Maria bought 1,702 shares. Lyra Therapeutics Inc shares valued at $5,725 were divested by the Officer at a price of $3.36 per share.
Jefferies downgraded its Lyra Therapeutics Inc [LYRA] rating to a Hold from a a Buy in a research note published on May 07, 2024; the price target was decreased to $0.50 from $10. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who decreased its forecast for the stock in early May from “a Buy” to “a Neutral”. BofA Securities also remained covering LYRA and has decreased its forecast on May 07, 2024 with a “an Underperform” recommendation from previously “Buy” rating. William Blair revised its rating on May 06, 2024. It rated LYRA as “a Mkt perform” which previously was an “an Outperform”.
Price Performance Review of LYRA
On Monday, Lyra Therapeutics Inc [NASDAQ:LYRA] saw its stock fall -45.31% to $2.06. Over the last five days, the stock has lost -39.05%. Lyra Therapeutics Inc shares have fallen nearly -79.47% since the year began. Nevertheless, the stocks have fallen -33.12% over the past one year.
How much short interest is there in Lyra Therapeutics Inc?
A steep rise in short interest was recorded in Lyra Therapeutics Inc stocks on 2025-12-31, dropping by 15739.0 shares to a total of 37456.0 shares. Yahoo Finance data shows the prior-month short interest on 2025-11-28 was 53195.0 shares. There was a decline of -42.02%, which implies that there is a negative sentiment for the stock.
